Relmada Therapeutics, Inc. · NASDAQ:RLMD

Relmada Therapeutics — Technical Presentation (October 2019)

8 slides from Relmada Therapeutics's technical presentation, Oct 21, 2019

  1. Slide 1: REL-1017-202 Phase 2 Study Top Line Results

    RELMADA THERAPEUTICS REL-1017-202 Phase 2 Study Top Line Results Ottavio V. Vitolo, M.D., M.M.Sc. SVP, Head of R&D and Chief Medical Officer Conference Call 15 October 2019

  2. Slide 2: REL-1017-202: a Phase 2 Study of REL-1017 at Two Doses in Subjects with Treatment Resistant Depression

    et ~ REL-1017-202: a Phase 2 Study of REL-1017 at Two Doses in Subjects with Treatment Resistant Depression SAFER interview - CTNI-MGH PEPPPRPPPRPPPRPPPPPPPEEP EEE PPP errr PEP PEP Study Day CI = Check-In; CRU = Clinical Research Unit: FU= Follow-Up

  3. Slide 3: Study REL-1017-202 Was Designed to Provide Data on Safety, PK and Efficacy

    —S—osSeQ"“(Q7~——_— } =—=@@m<— et RELMADA Study REL-1017-202 Was Designed to Provide Data on Safety, PK and Efficacy of REL-1017 in Treatment Resistant Depression Primary Objectives Primary Endpoints Safety and tolerability of 25 mg and 50 mg of REL-1017 vs Placebo as adjunctive treatment PE, Laborat

  4. Slide 4: Subjects' Disposition, Demographic Characteristics and Depression Severity Were Homogeneously Distributed Across Arms

    es et RELMADA Subjects’ Disposition, Demographic Characteristics and Depression Severity Were Homogeneously Distributed Across Arms Randomized Subjects Completed all visits 20 18 19 BY (Day 21) Received all doses Zl 19 il 61 Age: mean years (SD) 49.7 (11.1) 49.4 (12.4) 48.6 (10.9) 49.2 (11.3) Female

  5. Slide 5: Study REL-1017-202 Key Safety Findings

    RELMADA Study REL-1017-202 Key Safety Findings REL-1017-202 results confirm the favorable tolerability and safety profile observed in the Phase 1 SAD and MAD studies Only Mild and Moderate AEs - no SAEs No increased prevalence of specifically relevant organ group AEs in treatment groups vs placebo N

  6. Slide 6: Study REL-1017-202 Key Efficacy Findings

    RELMADA Study REL-1017-202 Key Efficacy Findings REL-1017 25 mg and 50 mg show rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures Solid efficacy results on MADRS with P values < 0.03 and large effect sizes (0.7- 1

  7. Slide 7: MADRS Scores in the Treatment Groups Achieved Statistically Significant Difference vs Placebo

    MADRS Scores in the Treatment Groups Achieved Statistically Significant Difference vs Placebo from Day 4 through Day 14 a ° a Least-Square Mean Change I) iS 25 Day 2 Treatment vs Placebo MADRS Change from Baseline - ITT Population == Placebo =A=REL-1017 25mg P = 0.0096; d = 0.8 P= 0.0308; d = 0.7 P

  8. Slide 8: CGI-S Scores Achieved Statistically Significant Difference vs Placebo

    ba CGI-S Scores Achieved Statistically Significant Difference vs “Placebo from Day 4 for REL-1017 50 mg and for both Doses on Day 7 and Day 14 CGI-S Change from Baseline - ITT Population 0 =@8—Placebo e=f==REL-1017 25 mg =O=REL -1017 50 mg © 05 [@>) Cc Oo < oO Cc -_ neha ca P-=0.0951;d=0.5 oO = o .

Relmada Therapeutics — Technical Presentation (October 2019) on 6ix